<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403038</url>
  </required_header>
  <id_info>
    <org_study_id>M12-673</org_study_id>
    <nct_id>NCT01403038</nct_id>
  </id_info>
  <brief_title>An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females</brief_title>
  <official_title>A Phase 1, Open-Label Study of the Effects of Elagolix on Ovarian Activity, Ovulation and Ovarian Reserve in Premenopausal Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects
      of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve
      and to assess the effect of elagolix on selected endocrine/hormone levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multiple-dose, Phase 1 study in premenopausal subjects aged 18 years
      to 40 years, with a history of regular menstrual cycles (24 to 32 days long) and no evidence
      of significant gynecological disorders. The objective of the study is to determine the
      effects of different dosing regimens of elagolix on ovulation, ovarian activity, and ovarian
      reserve. The study consists of 3 periods: a Screening Period of up to 50 days prior to the
      first dose, a Treatment Period of 3 months duration (Cycles 1-3), and a Follow-up Period of
      up to 60 days. During the Screening and Treatment menstrual cycles, serial transvaginal
      ultrasounds and determination of serum levels of luteinizing hormone, follicle-stimulating
      hormone, estradiol, progesterone, and inhibin B will be performed three times weekly.
      Subjects will maintain a daily diary of uterine bleeding. Pregnancy testing will be performed
      frequently throughout the study. Subjects will be required to use nonhormonal dual
      contraception consistently during the study, and will be counseled on appropriate and
      effective forms of birth control to promote pregnancy prevention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation Classification</measure>
    <time_frame>During the baseline menstrual cycle and monthly during the treatment cycles 1, 2, and 3 for up to month 3.</time_frame>
    <description>Presence or absence of ovulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ovarian Activity</measure>
    <time_frame>During the baseline menstrual cycle and monthly during the treatment cycles 1, 2, and 3 for up to month 3.</time_frame>
    <description>As measured by the Hoogland and Skouby 6-point ovarian activity grading system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters</measure>
    <time_frame>During the 16 week study period (4 week screening period and 12 week treatment period) for up to month 3</time_frame>
    <description>Estuarial, Progesterone, luteinizing hormone, follicle stimulating hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Reserve</measure>
    <time_frame>During the baseline menstrual cycle and monthly during the treatment cycles 1, 2, and 3 for up to month 3.</time_frame>
    <description>Inhibin-B and Antimullerian hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>All adverse events occurring through the Final Visit will be reported</time_frame>
    <description>All adverse events will be collected by subject self-report and review of laboratory parameters, physical exam. vital sign measurements and electrocardiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Change from baseline to Cycles 1, 2, and 3 or Final Visit</time_frame>
    <description>Chemistry, hematology, urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram</measure>
    <time_frame>Change from baseline to Week 4 and Final Visit</time_frame>
    <description>12-lead Electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Change from baseline to Cycles 1, 2, and 3 or Final Visit</time_frame>
    <description>Blood pressure, heart rate, temperature</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Folliculogenesis</condition>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose regimen 1 for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 2 for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 3 for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 4 for 84 days
Additional Dose Regimens may be added and will be administered for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 5 for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 6 for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose Regimen 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose Regimen 7 for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 1 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 1</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 2 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 2</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 3 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 3</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 4 for 84 days Other interventions may be added</description>
    <arm_group_label>Elagolix Dose Regimen 4</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 5 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 5</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix Dose Regimen 6 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 6</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elagolix</intervention_name>
    <description>Elagolix plus Activella Dose Regimen 7 for 84 days</description>
    <arm_group_label>Elagolix Dose Regimen 7</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Premenopausal female, between 18 and 40 years of age, inclusive - History of regular
        menstrual cycles - Endocrine and ultrasonographic evidence of ovulation and normal
        ovulatory cycle during the screening period - Follicle-stimulating hormone level of &lt;35
        mIU/mL - Agrees to use required birth control methods during the entire length of
        participation in the study

        Exclusion Criteria:

        - Screening ultrasound results show a clinically significant gynecological disorder -
        Surgical history of hysterectomy without oophorectomy, unilateral or bilateral
        oophorectomy, removal of ovarian cysts - Less than 6 months postpartum or post-lactation at
        the start of study drug dosing - Pregnant or breast feeding or is planning a pregnancy
        within the next 12 months - Testosterone concentration &gt;120 ng/dL at screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristof Chwalisz, MD, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50805</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 51270</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50884</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50404</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50904</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50402</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50808</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50807</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50804</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50762</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50403</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50810</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50883</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50803</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 51546</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50806</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 51342</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50811</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50902</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50882</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 53363</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 53362</name>
      <address>
        <city>Santurce</city>
        <zip>00910</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>elagolix</keyword>
  <keyword>endometriosis</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>gonadotropin-releasing hormone antagonist</keyword>
  <keyword>ovulation</keyword>
  <keyword>ovarian activity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

